Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2019

View Archived Issues

Mutation in MIR140 gene tied to skeletal dysplasia

Theranexus presents preliminary results of phase II study of THN-102 on patients with narcolepsy

Shionogi and Nagasaki University to collaborate in the field of infectious diseases

Hinova Pharmaceuticals describes new antitubercular compounds

Hiroshima University and collaborators present new PPIase Pin1 inhibitors

Technique boosts single-cell level grasp of DNA replication

ViiV Healthcare enters collaboration with Radboud University Medical Center

New STAT3 inhibitors discovered at King's College London

Amgen presents promising preclinical data for AMG-160

Teligene patents high affinity nerve growth factor receptor inhibitors

MDI-2268 shows safety and efficacy in murine model of deep vein thrombosis

Bromodomain-containing protein 4 inhibitors identified at Zhejiang Hisun Pharmaceutical

FDA allows initiation of phase I study of CT-044

AbCellera enters antibody discovery collaboration in neurology with Denali

Takeda Pharmaceutical presents the discovery of novel potent and selective Nav1.1 activator

Single-nulceotide polymorphism in ADGRL3 gene found predictor of substance use disorder

Azetidine optimization leads to clinical candidate JTE-952 for rheumatoid arthritis

Abpro and NJCTTQ partner to develop bispecific antibody therapies in immuno-oncology

Apellis enters collaboration with SFJ Pharmaceuticals for APL-2 in hematologic indications

Researchers find biomarkers associated with risk of GvHD

Minoryx receives Spanish clearance to begin phase II trial of MIN-102 in Friedreich's ataxia

Topivert Pharma initiates phase II/III study of TOP-1630 in dry eye syndrome

Armed oncolytic adenovirus targets tumor stroma to enhance viral spread

Phase III FORWARD I trial of mirvetuximab soravtansine does not meet primary endpoint

FDA approves Herceptin Hylecta for HER2-positive breast cancer